Summary
Epoetin theta, sold under the brand name Biopoin among others, is a copy of the human hormone erythropoietin.[1][2]
| Clinical data | |
|---|---|
| Trade names | Biopoin, Eporatio |
| License data |
|
| ATC code |
|
| Legal status | |
| Legal status | |
The most common side effects include shunt thrombosis (clots that can form in blood vessels of patients on dialysis, a blood clearance technique), headache, hypertension (high blood pressure), hypertensive crisis (sudden, dangerously high blood pressure), skin reactions, arthralgia (joint pain) and influenza (flu)-like illness.[1]Epoetin theta was approved for medical use in the European Union in October 2009.[1] It is on the World Health Organization's List of Essential Medicines.[3]
Medical uses edit
Epoetin theta is indicated for the treatment of symptomatic anemia in adults.[1]
References edit
- ^ a b c d e "Biopoin EPAR". European Medicines Agency (EMA). Retrieved 26 January 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Eporatio EPAR". European Medicines Agency (EMA). Retrieved 26 January 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
attribution contains material copied from Biopoin | European Medicines Agency https://www.ema.europa.eu/en/medicines/human/EPAR/biopoin 2021
External links edit
- "Epoetin theta". Drug Information Portal. U.S. National Library of Medicine.
